Zacks Research Has Bullish Forecast for Sanofi Q1 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Analysts at Zacks Research raised their Q1 2025 earnings estimates for Sanofi in a research report issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $0.85 for the quarter, up from their previous estimate of $0.84. The consensus estimate for Sanofi's current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi's Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th.

Sanofi Stock Down 0.7 %

NASDAQ SNY traded down $0.37 during trading on Monday, reaching $52.97. 2,123,042 shares of the company's stock were exchanged, compared to its average volume of 2,520,608. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The stock has a market cap of $134.43 billion, a P/E ratio of 27.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a 50 day moving average price of $48.90 and a two-hundred day moving average price of $52.22.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the previous year, the firm posted $2.55 earnings per share. The company's revenue was up 12.3% compared to the same quarter last year.

Institutional Trading of Sanofi

A number of large investors have recently made changes to their positions in the company. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $29,000. Synergy Asset Management LLC acquired a new position in Sanofi in the 4th quarter valued at about $25,000. Concord Wealth Partners raised its stake in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Sunbelt Securities Inc. lifted its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after acquiring an additional 313 shares during the period. Finally, Fortitude Family Office LLC grew its stake in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after purchasing an additional 659 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.